Social Icons

Thursday, December 29, 2011

Pharma deals may come under scanner


Corporate affairs ministry mulls changes in Competition Act, may provide different threshold for various sectors.
Pharma deals may not escape the scrutiny of the Competition Commission of India (CCI) on the ground of higher threshold that is provided in the Competition Act to trigger such a vetting. For, the Ministry of Corporate Affairs is mulling amending the legislation.
The Ministry of Corporate Affairs (MCA) is planning to amend the Competition Act, 2002, to introduce sector-specific assets and turnover thresholds for merger and acquisition (M&A) scrutiny.
While the move is primarily meant to empower the CCI to take up the scrutiny of all M&As happening in the domestic pharmaceutical space, it will make sector-specific exemptions, if required, easy across industrial sectors.
The ministry is known to have accepted a suggestion from the CCI to include a new section in the Act which allows the government to notify different value of assets and turnover for any class of enterprises in future.
Under the current rule, only those companies with Rs 750 crore asset value, or Rs 2,250 crore turnover, need to approach the CCI for M&A approvals. A high-level committee headed by Planning Commission member Arun Maira had, in October, said that this clause would keep most of the pharmaceutical acquisitions out of M&A scrutiny as a majority of pharma companies have annual revenues less than Rs 1,500 crore.
Hence, the Maira committee proposed changes in the rules framed under the Competition Act to bring all pharma M&A under CCI scrutiny. At this, the government, which approved the committee’s recommendation on October 10, set a six-month deadline for making rules.
The six-month deadline may not be met as amendment to the Act involves parliamentary approval, and is not as easy as notifying changes in the rules framed under the Act.
The ministry feels that changes in regulations alone cannot empower the CCI to undertake scrutiny of all pharma M&As, as the Act does not have an enabling provision.
Following the acceptance of the Maira committee recommendations, the government decided that India would continue to allow foreign direct investment without any limits (100 per cent) under the automatic route for greenfield investments in the pharma sector.
In the case of brownfield investments in the pharma sector, the decision taken was to allow FDI after getting it vetted by the Foreign Investment Promotion Board for a period of up to six months. During this period, the MCA was asked to make necessary enabling regulations to empower CCI for effective oversight on M&As.
Interestingly, the CCI can handle only competition issues; it has no powers to take a view on the basis of public health concerns. The commission will, therefore, have a “Standing Advisory Committee on Health and Pharmaceutical Sciences” constituted to advise the commission on the public health impact of pharmaceuticals M&A proposals.
The move to amend the Competition Act has come at a time when the country’s competition watchdog is engaged in signing a memorandum of understanding on competition-related matters with its counterparts in Russia and America.

Tuesday, December 27, 2011

Customer Realtionship Management

CRM is a business strategy that maximizes profitability, revenue and customer satisfaction by organizing around customer segments, fostering behavior that satisfies customers and implementing customer centric processes.

Types of CRM
  1. Strategic CRM
  2. Operational CRM
  3. Analytical CRM
  4. Collaborative CRM

Saturday, December 24, 2011

Pharma news-Sanofi Aventis Acquire Universal Medicare’s Nutraceutical Business

Aventis Pharma Limited (part of the Sanofi Group) announced on 24th August, 2011 that it has entered into a definitive agreement to acquire Universal Medicare Private Limited’s business of marketing and distribution of branded nutraceutical formulations in India. Also, approximately 750 commercial employees will transition to Aventis Pharma Ltd. The transaction has been approved by the Boards of Directors of both companies. It is expected to close in the fourth quarter of 2011, subject to certain conditions precedent.



Universal Medicare, (headquartered in Mumbai, India) manufactures, markets and distributes branded nutraceutical formulations in India through their sales and marketing infrastructure. For the year ended March 31, 2011, Universal Medicare’s turnover of the business to be acquired was approximately Rs. 1100 million.
With this acquisition, Aventis Pharma will advance its sustainable growth strategy in India and facilitate the creation of a consumer healthcare and wellness platform. This move is also synergetic with the growth strategy of Sanofi, a majority stakeholder in Aventis Pharma Limited.
“India is one of our most important markets in the emerging world and this acquisition reinforces our commitment to invest and grow our presence in India through a diversified portfolio that is focused on patients’ needs,” said Antoine Ortoli, Senior Vice President, Intercontinental Region – Global Operations of Sanofi.
“This strategic acquisition will allow Aventis Pharma and Sanofi Group to reach out to large sections of India’s population through a broad offering comprising of pharmaceuticals, vaccines and now nutraceuticals,” said Dr. Shailesh Ayyangar, Managing Director – Aventis Pharma Limited and Vice President – South Asia, Sanofi.
Universal Medicare’s portfolio of over 40 branded formulations represent key categories within the nutraceutical market, that are primarily antioxidants, vitamins and mineral supplements, anti-arthritics, anti-osteoporotics, liver tonics, and other nutrients.
Universal Medicare’s Chairman and Managing Director, Vikram Tannan stated “In today’s rapidly changing healthcare scenario, I believe that Aventis Pharma with its track record of building strong brands is best suited to take on and strengthen what we have built over the years. They will not only add value by giving new life to this business but will also nurture our employees through best in class training and advanced marketing practices in a multinational environment."
Under the proposed transaction, Universal Medicare will manufacture the products that Aventis Pharma will be acquiring on mutually agreed terms.
Source: Aventis Pharma

Tuesday, December 6, 2011

Nokia and Samsung INNOVATIVE ADVERTISING


The communication strategies used by both the companies are innovative showing the product in the ads that are shown on the websites.
The difference is that Nokia is trying to show the intangible or the part of ad concentrates on turning the phone into a wallet.It is focusing on the service part of the mobile phone.



Samsung placed its ad in economic times by  attracting the viewers with displaying the 'hot news' and issues on the screen.The image is from economic times website where the users are attracted to the latest and hot news and with the buttons similar to its product for sliding the news item on the screen.

Brands and Brand extension-article review


New Product launch has always been a popular strategy of the organisations to seek growth There are three broad strategies to launch a new product: (i) Line Extension; (ii) Brand Extension; and(iii) New Brand. 
Brand extension option has become an increasingly popular way to enhance the equity associated with well-known and well-respected brands Reduce introductory marketing expenses Reduce the risk of complicated buying decisions   Enhance the prospects of gaining access by helping retailer and consumer acceptance
BRAND EXTENSION
Using an existing brand name to promote a product in a different category, is Brand Extension or
Brand extension is using the leverage of a well known brand name in one category to launch a new product in a different category.
The key difference between line and brand extension is the product category.
In line extension the Product Category remains same whereas in brand extensions product category changes.
Authors of the research article-Dhananjay Bapat and J. S. Panwar-CONSUMER EVALUATION OF BRAND EXTENSIONS

Results of the study:There are certain associations which will be relevant for ensuring success in the extension category.
Two brand affects :
Strong brand associations
Borrowed factors
FINDINGS:
The findings show that extensions into similar categories tend to be more readily accepted. These findings are consistent across various product and service categories. Based on regression analysis, the study identifies brand relevance success factors. The findings indicate that success of brand extensions depends not only on strong parent brand associations but also on extendable category borrowed brand association
MANAGERIAL IMPLICATIONS:
Several implications for both brand management theory and practice
It underscores the importance of similarity in brand extension success evaluation
In the case of
Lux, Amul and Tata, there is a scope to leverage strong brand associations for ensuring success in the brand extension.
Extension advertisement emphasis
Brand associations help customers infer extension features and benefits.
Repeated exposure to appropriate brand association helps customers establish linkages between the brand and extension categories.
Brand associations play an important role in the brand extension success
CONCLUSION:
Organizations must look into the parent brand and check the brand associations of the parent brand when launching a product leveraging the parent brand.
The consumers always try to connect and evaluate the extension brands keeping the associations that are formed in their minds of the parent brand.
The expectations of the consumer are also framed by them and expects the benefits which are physical as well as Intangible benefits.
so, Organizations have to look into all these aspects and must take a decision while launching a brand, whether to leverage the parent brand or they have to launch a new brand all together.


Monday, November 28, 2011

Group discussion

Just post  ur topics...we will discuss it here and can have different views on it.

Tuesday, November 22, 2011

Review on zenni opticals

ZenniOptical is the #1 online eyeglasses store offering high quality prescription eyeglasses from $6.95. Eyeglasses are definitely a personal fashion and style item.
Website: www.zennioptical.com
Product: Prescription eyeglasses Price range: $6 to $45 With Various benefits of thin and light lens, UV protection, Anti glare, sunglass tint,etc
Unique selling proposition (USP): FASHIONABLE AND TRENDY GLASSES
Target market : It caters all segments of Price range from $6 to $46 with all the benefits and covering all range of material and population of all ages.
 Marketing strategy used by the company: "Customisation" of product according to the gender,size, shape, color and material to be used and meeting the specifications of the customer.
 Delivery process: online order is delivered to home and free shipping on order above $50

Monday, November 14, 2011

International Business-Food chain- assignment -expansion-FOOD CHAIN ENTERING U.S

INTERNATIONAL BUSINESS PROJECT :FOOD CHAIN ENTERING U.S Saucy Samoz Introduction: Saucy samoz brings you a full range of tasty, authentic Indian snacks, Appetizers and Entrees. All our products are manufactured in the USA. We use only the finest and most authentic ingredients from India to ensure ‘true’ flavor and serve the customers with innovation in the process and products with best practices in cooking providing customer delight and achieving customer confidence. DOWNLOAD LINK: http://turboupload.com/mmarozr1vf3s

Saturday, November 5, 2011

MBA-PGDM-TAJ ICE CREAM BHINDI BAZAAR, MUMBAI

TAJ ICE CREAMS is located in Bhindi Bazaar, Mumbai LINK TO NOTES: http://turboupload.com/j8wkvvhyxvie

The essential dimensions for an Indian Entrepreneur

The two dimensions that are essential for the entrepreneur are 1.Visionary Dimension 2.Architectural dimension Visionary Dimension: -be able to see the the future of the company -able to scale up the company in the future -predictability of the customer needs and the future changes Architectural dimension -be able to clear idea on the processes, procedures,the operations -develop the operational capabilities to meet the customer needs and should be able to adapt to those changes.

Thursday, October 20, 2011

Blog Advertising - Advertise on blogs with SponsoredReviews.com

MBA-PGDM-six sigma-efficient supply chain management-mumbai dabbawalas

  • DABBAWALAS: their work is to carry the tiffin boxes from the houses to the offices for their lunch the employees who cannot carry their lunch early in the morning.
  • Core work: Delivery
  • Principles followed : and PRACTICED
    • customer is the god
    • dedication 
    • discipline
    • responsibility acceptance and maintenance
    • teamwork and coordination
    • knowing the consequences of error-avoiding it 100%
      • Started in 1890
      • Charitable trust: Registered in 1956
      • Avg. Literacy Rate: 8th Grade Schooling
      • Total area coverage: 60 Kms to 70 Kms
      • Employee Strength: 5000
      • Number of Tiffin's: 2,00,000 Tiffin Boxes i.e 4,00,000 transactions every day.
      • Time taken: 3 hrs

      Error Rate: 1 in 16 million transactions
  • Six Sigma performance (99.999999)
  • Technological Backup: Nil.
  • Cost of service - Rs. 300/month ($ 6.00/month)
  • Standard price for all (Weight, Distance, Space)
  • Rs. 36 Cr. Turnover approx. [6000*12*5000=360000000 i.e Rs. 36 crore p.a.]
  • “No strike” record as each one a share holder
  • Earnings -5000 to 6000 p.m.
  • Diwali bonus: one month's from customers
  • Zero % fuel
  • Zero % modern
    technology
  • 99.9999% performance
  • Zero % investment
  • 100 % Customer Satisfaction
  • Zero % Disputes
Disciplines
  • No Alcohol Drinking during business hours
  • Wearing White Cap during business hours
  • Carry Identity Cards
  DELIVERY SYSTEM BY CODING
Coding System.........
 
VLP : Vile Parle (suburb in Mumbai)
9EX12 : Code for Dabbawalas at Destination
EX : Express Towers (building name)
12 : Floor no.
E : Code for Dabbawala at residential station
3 : Code for destination Station eg. Churchgate Station (Nariman Point)
Let us now look at an example of these codes on the Tiffin's to better understand the system and what it all denotes.
 
 

Wednesday, October 19, 2011

OPERATIONS STRATEGY

What is a strategy?
which has a time frame (usually long term,according to the situtation) and course of action and the actions which cannot be taken back, coz we incur loss as we take decisions to them them for the long term.
Devising and implementing processes that will enable as well as exploiting oppurtunities for potential market segments.
Developing the capabilities within the firm operations that are superior than that of our competitors and competitor cannot copy and difficult to copy.
what are all the issues of operations ,where we apply strategies?
Location
Product
Layout
Inventory
Supply chain
Quality
Innovation

heart and water

HEART & WATER
DRINK WATER ON EMPTY STOMACH
It is popular in Japan today to drink water immediately after waking up every morning. Furthermore, scientific tests have proven its value. We publish below a description of use of water for our readers. For old and serious diseases as well as modern illnesses the water treatment had been found successful by a Japanese medical society as a 100% cure for the following diseases:
Headache, body ache, heart system, arthritis, fast heart beat, epilepsy, excess fatness, bronchitis asthma, TB, meningitis, kidney and urine diseases, vomiting, gastritis, diarrhea, piles, diabetes, constipation, all eye diseases, womb, cancer and menstrual disorders, ear nose and throat diseases.
METHOD OF TREATMENT
1. As you wake up in the morning before brushing teeth, drink 4 x 160ml glasses of water
2. Brush and clean the mouth but do not eat or drink anything for 45 minute
3.. After 45 minutes you may eat and drink as normal.
4. After 15 minutes of breakfast, lunch and dinner do not eat or drink anything for 2 hours
5. Those who are old or sick and are unable to drink 4 glasses of water at the beginning may commence by taking little water and gradually increase it to 4 glasses per day.
6. The above method of treatment will cure diseases of the sick and others can enjoy a healthy life.
The following list gives the number of days of treatment required to cure/control/reduce main diseases:
1. High Blood Pressure (30 days)
2. Gastric (10 days)
3. Diabetes (30 days)
4. Constipation (10 days)
5. Cancer (180 days)
6. TB (90 days)
7. Arthritis patients should follow the above treatment only for 3 days in the 1st week, and from 2nd week onwards – daily..
This treatment method has no side effects, however at the commencement of treatment you may have to urinate a few times.
It is better if we continue this and make this procedure as a routine work in our life. Drink Water and Stay healthy and Active.
This makes sense .. The Chinese and Japanese drink hot tea with their meals ..not cold water. Maybe it is time we adopt their drinking habit while eating!!! Nothing to lose, everything to gain...
For those who like to drink cold water, this article is applicable to you.
It is nice to have a cup of cold drink after a meal. However, the cold water will solidify the oily stuff that you have just consumed. It will slow down the digestion.
Once this 'sludge' reacts with the acid, it will break down and be absorbed by the intestine faster than the solid food. It will line the intestine.
Very soon, this will turn into fats and lead to cancer. It is best to drink hot soup or warm water after a meal.
A serious note about heart attacks:
· Women should know that not every heart attack symptom is going to be the left arm hurting,
· Be aware of intense pain in the jaw line.
· You may never have the first chest pain during the course of a heart attack.
· Nausea and intense sweating are also common symptoms.
· 60% of people who have a heart attack while they are asleep do not wake up.
· Pain in the jaw can wake you from a sound sleep. Let's be careful and be aware. The more we know, the better chance we could survive..

Wednesday, October 12, 2011

NEED ANALYSIS: 6 Principles of Needs Analysis

NEED ANALYSIS: Needs analysis is defined as a formal process focus on how a product addresses the needs of a human. It is not an official business development tool, but is considered a valuable analytical technique to better gauge the marketability of a product or a service to a human consumer. It is often used across many industries, such as software development, automobiles, consumer products and banking services. Needs analysis was originally used for software developers, who used the system in tandem with requirements analysis – a study of the elements represented within a system. In short, if these two systems were applied to Apple Inc., requirements analysis would be involved with all the internal guts of the computers, the ugly complicated bits of hardware and firmware that are hidden from the end user; while needs analysis would be focused on the slick software operating system interface as well as its peripherals – such as the keyboard and mouse – that are directly used by the end user – and as such, affect the end user’s final perception of the product.

6 Principles of Needs Analysis

  • The opinion of end users is essential to unify a diverse, opinionated design team, and their opinion should transcend the desires of your design team.
  • Market research is essential to unify end user opinions, and to use quantitative and qualitative research to find the best direction for product or service designs.
  • Appeal to the lowest common denominator in end user needs. Marketing to the lowest skill levels results in the largest potential market. In other words, follow the KISS principle – “keep it simple, stupid”.
  • Do comprehensive beta tests of your products over a long period of time to allow adequate adjustments before “freezing” your product for the final manufacturing stage.
  • Continue to monitor user feedback after the product launch, and address defects quickly and keep an accurate record to apply to future releases, if they cannot be addressed immediately in the current product.
  • Elegant designs are the end product of successful needs analysis, and will put your product head and shoulders above industry peers.
Gap analysis, which is used to compare actual business performance with ideal performance, is often used in conjunction with needs analysis to maximize a business’ growth potential. Gap analysis insures that a company is allocating its resources for maximum production. Gap analysis is considered a benchmarking tool for efficiency and is used for outlining a clearer road map for future growth, and can be used at both the strategic and operational levels of an organization. In short, it tries to fill the “gap” between where a company is, and where it aims to be. In addition, some organizations referred to “gap” as an acronym – separating the “good”, “average” and “poor” aspects of a business.

Monday, October 10, 2011

Reliance Industries to sign deal with Disney's UTV - report




The main gate of entertainment giant Walt Disney Co. is pictured in Burbank, California May 5, 2009. Disney is scheduled to report its second-quarter earnings May 5, 2009.  REUTERS/Fred Prouser/Files

MUMBAI | Mon Oct 10, 2011 12:36pm IST
(Reuters) - Reliance Industries, India's largest listed firm, is set to sign a deal with the Indian unit of Walt Disney, to acquire content for its telecom operations, the Financial Times said.
The deal by Reliance with UTV Software, in which Disney controls 50.44 percent, is expected to be completed in the coming weeks, the newspaper said late on Sunday, citing people close to the development.
UTV Software said it had no immediately comment on the report, while Reliance could not be immediately reached.
Reliance, which has diversified into telecom, retail, financial services and hospitality sectors in recent years from its core business of refining and oil and gas exploration, last year acquired Infotel, which emerged as the only firm to secure nationwide wireless broadband radio airwaves in an auction.
The deal is expected to give Reliance access to games, entertainment and children's content for their telecom operations, the paper said.
Reliance has plans of building a data-focused business which will provide mobile, smartphone, tablet and computer users access to the net and online related services via a wireless broadband network.
The diversified company, which has been under pressure from falling gas output, has pushed for tie-ups in recent months to boost its business.
In June, Reliance signed a joint venture with DE Shaw, a U.S. hedge fund, for acquiring Bharti Enterprises 74 percent stake in an insurance joint venture with France's Axa.
The following month the Indian cabinet approved Reliance's plan to sell a stake in 21 of 23 planned oil and gas blocks to BP as part of a $7.2 billion deal.
At 10:24 a.m. (0454 GMT), shares in Reliance, valued at $53.5 billion, were up 1.5 percent at 815 rupees in a firm Mumbai market.
The stock has been a laggard, falling 24 percent in the year to date compared with a 21 percent drop in the main index, largely due to falling gas output.

Thursday, October 6, 2011

List of Drugs Banned in India by the Ministry of Health and Family Welfare


Drugs Prohibited from the date of Notification
  1. Amidopyrine.
  2. Fixed dose combinations of vitamins with anti–inflammatory agents and tranquilizers.
  3. Fixed dose combinations of Atropine in Analgesics and Antipyretics.
  4. Fixed dose combinations of Strychnine and Caffeine in tonics.
  5. Fixed dose combinations of Yohimbine and Strychnine with Testosterone and Vitamins.
  6. Fixed dose combinations of Iron with Strychnine, Arsenic and Yohimbine.
  7. Fixed dose combinations of Sodium Bromide/chloral hydrate with other drugs.
  8. Phenacetin.
  9. Fixed dose combinations of antihistaminic with anti-diarrhoeals.
  10. Fixed dose combinations of Penicillin with Sulphonamides.
  11. Fixed dose combinations of Vitamins with Analgesics.
  12. Fixed dose combinations of any other Tetracycline with Vitamin C.
  13. Fixed dose combinations of Hydroxyquinoline group of drugs with any other drug except for preparations meant for external use.
  14. Fixed dose combinations of Corticosteroids with any other drug for internal use.
  15. Fixed dose combinations of Chloramphenicol with any other drug for internal use.
  16. Fixed dose combinations of crude Ergot preparations except those containing Ergotamine, Caffeine, analgesics, antihistamines for the treatment of migraine, headaches.
  17. Fixed dose combinations of Vitamins with Anti TB drugs except combination of Isoniazid with Pyridoxine Hydrochloride (Vitamin B6).
  18. Penicillin skin/eye Ointment.
  19. Tetracycline Liquid Oral preparations.
  20. Nialamide.
  21. Practolol.
  22. Methapyrilene, its salts.
  23. Methaqualone.
  24. Oxytetracycline Liquid Oral preparations.
  25. Demeclocycline Liquid Oral preparations.
  26. Combination of anabolic Steroids with other drugs.
  27. Fixed dose combination of Oestrogen and Progestin (other than oral contraceptive) containing per tablet estrogen content of more than 50 mcg (equivalent to Ethinyl Estradiol) and progestin content of more than 3 mg (equivalent to Norethisterone Acetate) and all fixed dose combination injectable preparations containing synthetic Oestrogen and Progesterone. (Subs. By Noti. No. 743 (E) dt 10-08-1989)
  28. Fixed dose combination of Sedatives/ hypnotics/anxiolytics with analgesics-antipyretics.
  29. Fixed dose combination of Rifanpicin, isoniazid and Pyrazinamide, except those which provide daily adult dose given below:
    Drugs Minimum Maximum
    Rifampicin 450 mg 600 mg
    Isoniazid 300 mg 400 mg
    Pyrazinamide 1000mg 1500 mg
  30. Fixed dose combination of Histamine H-2 receptor antagonists with antacids except for those combinations approved by Drugs Controller, India.
  31. The patent and proprietary medicines of fixed dose combinations of essential oils with alcohol having percentage higher than 20% proof except preparations given in the Indian Pharmacopoeia.
  32. All Pharmaceutical preparations containing Chloroform exceeding 0.5% w/w or v/v whichever is appropriate.
  33. Fixed dose combination of Ethambutol with INH other than the following: INH Ethambutol 200 mg. 600 mg. 300 mg. 800 mg.
  34. Fixed dose combination containing more than one antihistamine.
  35. Fixed dose combination of any anthelmintic with cathartic/purgative except for piperazine/Santonim.
  36. Fixed dose combination of Salbutamol or any other bronchodilator with centrally acting anti-tussive and/or antihistamine.
  37. Fixed dose combination of laxatives and/or anti-spasmodic drugs in enzyme preparations.
  38. Fixed dose combination of Metoclopramide with systemically absorbed drugs except fixed dose combination of metoclopramide with aspirin/paracetamol
  39. Fixed dose combination of centrally acting, antitussive with antihistamine, having high atropine like activity in expectorants.
  40. Preparations claiming to combat cough associated with asthma containing centrally acting antitussive and/ or an antihistamine.
  41. Liquid oral tonic preparations containing glycerophosphates and/or other phosphates and / or central nervous system stimulant and such preparations containing alcohol more than 20% proof.
  42. Fixed dose combination containing Pectin and/or Kaolin with any drug which is systemically absorbed from GI tract except for combinations of Pectin and/or Kaolin with drugs not systemically absorbed.
  43. Chloral Hydrate as a drug.
  44. Dovers Powder I.P.
  45. Dover’s Powder Tablets I.P.
  46. Antidiarrhoeal formulations containing Kaolin or Pectin or Attapulgite or Activated Charcoal.
  47. Antidiarrhoeal formulations containing Phthalyl Sulphathiazole or Sulphaguanidine or Succinyl Sulphathiazole.
  48. Antidiarrhoeal formulations containing Neomycin or Streptomycin or Dihydrostreptomycin including their respective salts or esters.
  49. Liquid Oral antidiarrhoeals or any other dosage form for pediatric use containing Diphenoxylate Lorloperamide or Atropine or Belladona including their salts or esters or metabolites Hyoscyamine or their extracts or their alkaloids.
  50. Liquid Oral antidiarrhoeals or any other dosage form for pediatric use containing halogenated hydroxyquinolines.
  51. Fixed dose combination of antidiarrhoeals with electrolytes.
  52. Patent and Proprietary Oral Rehydration Salts other than those conforming to the
  53. Fixed dose combination of Oxyphenbutazone or Phenylbutazone with any other drug.
  54. Fixed dose combination of Analgin with any other drug.
  55. Fixed dose combination of dextropropoxyphene with any other drug other than anti-spasmodics and/or non-steriodal anti-inflammatory drugs (NSAIDS).
  56. Fixed dose combination of a drug, standards of which are prescribed in the Second Schedule to the said Act with an Ayurvedic, Siddha or Unani drug.
  57. Mepacrine Hydrochloride (Quinacrine and its salts) in any dosage form for use for female sterilization or contraception.
  58. Fenfluramine and Dexfenfluramine.
  59. Fixed dose combination of Diazepam and Diphenhydramine Hydrochloride.
  60. Rimonabant.
  61. Rosiglitazone
  62. Nimesulide formulations for human use in children below 12 years of age.
  63. Cisapride and its formulations for human use.
  64. Phenylpropanolamine and its formulation for human use.
  65. Human Placental Extract and its formulations for human use.
  66. Sibutramine and its formulations for human use, and
  67. R-Sibutramine and its formulations for human use.
  68. Gatifloxacin formulation for systemic use in human by any route including oral and injectable
  69. Tegaserod and its formulation for human use.

Saturday, September 24, 2011

A BREAK THROUGH IN CANCER TREATMENT: VIRUS THAT TREATS CANCER





WHAT IS CANCER?



We will discuss in brief about cancer. Cancer is a large, heterogeneous class of diseases in which a group of cells display uncontrolled growth, invasion that intrudes upon and destroys adjacent tissues, and often metastasizes, wherein the tumor cells spread to other locations in the body via the lymphatic system or through the bloodstream.



An Ottawa-based research team has developed a virus that is showing promise as a new way of attacking and shrinking cancer tumours while leaving healthy tissue alone.
It's early days in the still-experimental field of therapeutic cancer viruses, called oncolytic viruses. But this new study from researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa advances the field a little further by showing that the virus is safe in most patients.
For the study, researchers recruited 23 advanced cancer patients whose cancer had spread to multiple organs. All had failed to respond to the usual treatments and all were in the final stages of the disease.

The patients agreed to receive a single infusion of an experimental virus into their blood, called JX-594.
JX-594 is a form of vaccinia virus that's been used as a live vaccine against smallpox. The JX-594 virus has been genetically engineered to enhance its natural anti-cancer properties. The virus is not smallpox and it's not strong enough to infect healthy cells, but tumour cells, which are inherently weak, are susceptible to it.
The doctors tried out five doses of the virus, and then took biopsies of the tumours eight to 10 days later.
The researchers found that seven of the eight patients in the highest dose groups had evidence that the virus was in place and replicating in their tumours and not in normal tissues.
What's more, six of eight patients in the two highest dose groups experienced a shrinking or stabilization of their tumours, while those in lower dose groups saw less of this effect.
None of the 23 patients experienced significant side effects from the virus injection, with the most common side effect being mild to moderate flu-like symptoms that lasted less than one day.
The study, which is published in the journal Nature, was designed primarily to test the safety of the virus, not to cure the patients. In fact, some of the patients later died of their disease.
But the observation that some patients saw their tumours shrink was a welcome discovery.
Dr. John Bell, one of the study's co-authors and a researcher at OHRI says it's exciting that the virus led to results after just one dose.
"Of course, we will need to do more trials to know if this virus can truly make a difference for patients," he said in a statement.
Bell says the advantage of therapeutic viruses is that they can be sent through the blood, infect the cancer tumours and leave the healthy tissue alone. It's possible that oncolytic viruses could one day offer an alternative to conventional chemotherapy and radiation treatment, which tend to destroy healthy cells as well as cancer cells.
"Oncolytic viruses are unique because they can attack tumours in multiple ways, they have very mild side effects compared to other treatments, and they can be easily customized for different kinds of cancer," Bell said.
"We're still in the early stages of testing these viruses in patients, but I believe that someday, viruses and other biological therapies could truly transform our approach for treating cancer."
JX-594 was developed with Jennerex Inc., a biotherapeutics company co-founded by Dr. Bell in Ottawa and Dr. David Kirn in San Francisco.
The study was funded in part by Jennerex, as well as the Terry Fox Foundation, the Canadian Institutes of Health Research and the Ontario Institute for Cancer Research, and others.
Bell and his research team plan to do further tests on many more patients to show the treatment actually works and that the body doesn't learn to resist the virus over time.
A Phase 2 trial is to start soon aimed at patients with end-stage liver cancer or colon cancer.

Wednesday, September 21, 2011

Marketing Research Proposal

Marketing Research Proposal Executive summary -- the proposal should begin with a summary of the major points from each of the other sections, presenting an overview of the entire proposal Background -- the background of the problem, including the environmental context, should be discussed Problem definition/objectives of the research -- normally a statement of the problem, including the specific components, should be presented. If this statement has not been developed (in the case of problem identification research), the objectives of the marketing research project should be clearly specified approach to the problem -- at a minimum, a review of the relevant academic and trade literature should be presented, along with some kind of analytical model. If research questions and hypotheses have been identified, then he should be included in the proposal Research design -- the research designed adopted, whether exploratory, descriptive, or casual, should be specified. fieldwork/data collection -- the proposal should discuss how the data will be collected and he will collect it. If the field work is to be subcontracted to another supplier, this should be stated. Control mechanisms to ensure the quality of data collected should be described Data analysis -- the kind of data analysis that will be conducted and how the results will be interpreted should be described Reporting -- the proposal should specify whether intermediate reports will be presented and at what stages, what will be the form of the final report, and whether a formal presentation of the results will be made Cost and time -- the cost of the project and a time schedule, broken down by phases, should be presented. A CPM or PERT chart might be included. In large projects, a payment schedule is also worked out in advance Appendices -- any statistical or other information that is of interest to only a feed people should be contained in appendices

Nissan Sunny unveiled in India at Rs 5.78 lakh

Nissan Motor India has unveiled a mid-size sedan Sunny, which is priced in the range of Rs 5.78 lakh - Rs 7.68 lakh.
After the Nissan Micra, this is the auto manufacturer's second locally-made mass-market product, which it aims to give higher volumes in the upcoming festive season.
Moreover, the prices are uniform across India, though the sedan will be available in the initial stage only as a petrol model. The bookings of Nissan Sunny will commence from today and the deliveries will start from October 3. The Nissan Sunny will be giving strong competition to other vehicles like Maruti Suzuki Swift Dzire, Toyota Etios and Volkswagen Vento.

SkodaAuto India----premium sedan Laura RS

Laura RS
Car-maker SkodaAuto India has launched a new edition of its premium sedan Laura RS in India, priced at Rs 15.49 lakh (ex-showroom, Delhi).

Renault to commence phase II of India market strategy, plans new products to launch next year

French commercial vehicle manufacturer Renault, is all to commence the second phase of the India market strategy after the successful first phase completion this month with the establishment of its Fluence sedan and Koleos SUV brands in the premium car segment.
As per the business strategy for the second phase, the company may roll out an all new small car in the first few months of 2012. The new launches will be based on the same V-platform that supports the Nissan Micra and Sunny.
The new product are designed under the consideration of Indian market and will compete with Maruti Suzuki's Swift and the Hyundai i20. Moreover, in mid-2012 the company will launch its fourth product the SUV Duster which will compete with Mahindra's Scorpio and the Tata Safari.
As per the dealer of the company, the fifth product of the company, a new sedan, is positioned between the Volkswagen Vento and the Swift Dzire, is scheduled to be launched in the late next year. All planned 12 products are expected to come in by 2014.
Mr Len Curran, Vice-President, Sales and Marketing, Renault India, said, “Our target is to reach one lakh units by 2013. The two new vehicles will have above 60 per cent localisation and India will be the first market for this small car.”

Mylan's Indian arm Matrix Labs gets tentative approval from USFDA for AIDS tablets

 Matrix Laboratories, the Indian arm of drugmaker Mylan Inc, has received the tentative approval from the US Food and Drug Administration (USFDA) to market its generic Lamivudine, Tenofovir Disoproxil Fumarate tablets, used for treatment of AIDS/HIV.
Under the granted approval, Matrix Laboratories is permitted to market Lamivudine, Tenofovir Disoproxil Fumarate tablets in the strengths of 300 mg co-packaged with Nevirapine tablets in the strength of 200 mg.
Mr Heather Bresch, Mylan President, said, “The approval of Lamivudine, Tenofovir Disoproxil Fumarate tablets co-packaged with Nevirapine tablets is an important product developed by Matrix for the treatment of HIV/AIDS.”
Mr Robert J Coury, Mylan Vice Chairman and CEO, said, “This product approval is yet another important step in providing access to a range of critical HIV medications to patients in developing countries. Mylan and Matrix continue to make a significant contribution to bringing down the cost of these vital treatments through the expansion of our high-quality anti-retroviral franchise.”
The company secured the tentative approval from the US Food and Drug Administration (USFDA) through the President's Emergency Plan for AIDS Relief (PEPFAR).

Bayer Healthcare to acquire Pathway Medical Technologies

Bayer Healthcare to acquire Pathway Medical Technologies

Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases

Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases

Tuesday, September 13, 2011

Management Lessons from ‘3 Idiots’ Movie

1. Never Try To Be Successful
Success is the bye-product. Excellence always creates success. So, never run after the success, let it happen automatically in the life.


2. Freedom To Life
Don’t die before actual death. Live every moment to the fullest as you are going to
die today night. Life is gifted to humankind to live, live & live @ happiness.
3. Passion Leads To Excellence
When your hobby becomes your profession and passion becomes your profession. You will be able to lead up to excellence in the life. Satisfaction, pleasure, joy and love will be the outcome of following passion. Following your passion for years, you will surely become something one day.


4. Learning Is Very Simple
Teachers do fail. Learners never fail. Learning is never complicated or difficult. Learning is always possible whatever rule you apply.

5. Pressure At Head
Current education system is developing pressures on students’ head. University intelligence is useful and making some impact in the life but it cannot be at the cost of the life.


6. Life Is Emotion Management Not Intelligence Optimization 
Memory and regular study have definite value and it always helps you in leading a life. You are able to survive even if you can make some mark in the path of the life. With artificial intelligence, you can survive and win but you cannot prove yourself genius. Therefore, in this process genius dies in you.

7. Necessity Is The Mother Of Invention

Necessity creates pressure and forces you to invent something or to make it happen or to use your potentiality. Aamir Khan in this film, 3 idiots, is able to prove in the film by using vacuum pump at the last moment.


8. Simplicity is Life
Life is need base never want base. Desires have no ends. Simplicity is way of life and Indian culture highly stresses on simple living and high thinking, and this is the way of life: ‘Legs down to earth and eyes looking beyond the sky’


9. Industrial Leadership
Dean of the institute in 3 idiots is showing very typical leadership. He has his own principles, values and ideology, and he leads the whole institute accordingly. This is an example of current institutional leadership. In the present scenario, most of the institutes are fixed in a block or Squarish thinking.


10. Love Is Time & Space Free
Love is not time bound and space bound. It is very well demonstrated in this movie same love was demonstrated by Krishna and Meera. Love is border free, time free and space free.

11. Importance Of One Word In Communication 

If communication dies, everything dies. Each word has impact and value in communication. One word if used wrongly or emphasized wrongly or paused at a wrong place in communication what effect it creates and how is it affected is demonstrated very well in this movie.
12. Mediocrity Is Penalized
Middle class family or average talent or average institute is going to suffer and has to pay maximum price in the life if they do not upgrade their living standards. To be born poor or as an average person is not a crime but to die as an average person with middle class talent is miserable and if you are unable to optimize your potentiality and die with unused potentiality then that is your shameful truth. One should not die as a mediocre. He/she has to bring out genius inside him/her and has to use his/her potentiality to the optimum level.





Top 5 hollywood movies to be watched


Baby Boom
Glengarry Glen Ross

Up in the Air


The Pursuit of Happiness

Jerry Maguire


 
 
Blogger Templates